Glycine, Glutamate Signalling, and Divergent Neurobiology: A Missing Link in OCD, BDD, Metabolic Stress, and Excitotoxicity?

Disclaimer: I use scientific terminology in my research because I write academically. However, I do not always agree with the framing of the terminology used, even where it may be 'technically' accurate. In such cases, I place the terminology in single quotation marks.

A case report (link below) on high-dose glycine treatment for severe, treatment-resistant obsessive-compulsive disorder and body dysmorphic 'disorder' is striking because it reveals a much deeper biological possibility: in at least some individuals, obsessive-compulsive and body-focused psychiatric symptoms may emerge through a convergence of disrupted glutamatergic signalling, divergent NMDA receptor function, metabolic stress, immune activation, and altered substrate availability.

In this reported case, the individual developed obsessive compulsive 'disorder' (OCD) and body dysmorphic 'disorder' (BDD) around age 17, became socially isolated and housebound, failed to respond to multiple selective serotonin reuptake inhibitors and atypical neuroleptics, and later experienced major symptom exacerbations following infections and antibiotic exposure. Treatment with high-dose glycine, described by the authors as an NMDA receptor co-agonist, was associated with substantial symptom reduction over five years, with relapses occurring when treatment was stopped and improvement returning after resumption. Education and social life were reportedly resumed. The authors explicitly framed the case around deficient NMDA receptor signal transduction rather than a conventional serotonin-deficiency model.

Glycine is the smallest amino acid, but it sits at the intersection of several systems that are highly relevant to divergent physiology: collagen structure, glutathione synthesis, detoxification, bile acid conjugation, methylation balance, immune regulation, and neurotransmission. It acts as an inhibitory neurotransmitter in parts of the central nervous system, especially the spinal cord and brainstem, but it also functions as a required co-agonist at NMDA-type glutamate receptors. NMDA receptors are a major subtype within the wider glutamate system and are central to synaptic plasticity, learning, memory, signal updating, and calcium-mediated neuronal adaptation.

This is where the connection to divergent neurobiology becomes important. Glutamate is the brain’s main excitatory neurotransmitter, and multiple reviews have linked autism and related neurodevelopmental profiles with altered glutamatergic signalling, including differences in glutamate receptors, glutamate metabolism, synaptic signalling, and excitatory–inhibitory balance.

Recent autism research has also focused on specific glutamate receptor systems, including metabotropic glutamate receptor 5, or mGlu5, as part of the broader excitatory–inhibitory imbalance model.

The key point is that glutamate signalling is not one pathway; it includes NMDA receptors, AMPA receptors, metabotropic glutamate receptors, glutamate transporters, astrocyte clearance systems, GABA conversion pathways, calcium channels, mitochondrial buffering, and antioxidant systems. NMDA receptors are one of the most important nodes in this network because they link excitatory signalling directly to calcium entry and plasticity. In the correct context, NMDA signalling supports learning and adaptive updating. In the wrong context - inflammation, mitochondrial stress, impaired antioxidant buffering, poor glutamate clearance, or receptor dysregulation - the same system can become excitotoxic.

This gives us a more nuanced framework for understanding divergent susceptibility. Divergent populations have different excitatory thresholds, receptor dynamics, clearance capacity, calcium sensitivity, and metabolic buffering. Therefore, the issue is not merely neurotransmitter quantity, but system regulation. The same signal that supports heightened perception, pattern recognition, sensory intensity, or rapid associative thinking may become damaging when the surrounding metabolic terrain cannot buffer it.

Glycine is also a structural amino acid heavily required for collagen. Collagen contains glycine at every third position in its repeating amino acid structure, making glycine central to connective tissue formation and repair. Reviews increasingly describe glycine as conditionally essential: the body can make it, mainly from serine, but endogenous synthesis may not always meet demand, especially under states of growth, pregnancy, metabolic stress, inflammation, malnutrition, diabetes, insulin resistance, or high xenobiotic exposure.

This is relevant for people with collagen variants, connective tissue vulnerability, metabolic 'disorders', mitochondrial stress, or fatty acid oxidation 'disorders'. In long-chain fatty acid oxidation 'disorders', the body has difficulty using long-chain fats efficiently for energy, particularly during fasting, illness, stress, or exertion. When fat oxidation is impaired, the body may become more dependent on glucose, amino acids, gluconeogenesis, protein turnover, and emergency metabolic compensation. Amino acids therefore become part of the body’s repair, stress-response, detoxification, and energy-substitution economy.

For someone with both divergent fatty acid oxidation and collagen-related vulnerability, the demand on glycine would plausibly be higher than average. Glycine may be needed simultaneously for connective tissue repair, glutathione synthesis, bile handling, methylation buffering, and nervous-system regulation. This does not mean every person with a metabolic 'disorder' is automatically glycine-deficient. The more precise term is amino acid economy disruption: a state in which intake, synthesis, recycling, demand, diversion, and loss no longer line up cleanly.

This framing also helps reinterpret OCD and BDD in a more biologically sophisticated way. OCD and BDD are usually placed within psychiatric categories, but the biology underneath them may vary between individuals. OCD has been repeatedly associated with glutamate abnormalities, and glutamate-modulating agents have been investigated for OCD and related disorders, although no glutamate-targeting treatment is currently established as universally effective.

At least some obsessive-compulsive presentations may involve neural updating, threat-loop reinforcement, cortico-striatal rigidity, salience misassignment, or excitatory–inhibitory imbalance rather than the outdated seratonin imbalance theory.

In the aforementioned case report, the history of symptom exacerbation following infections and antibiotic exposure is also notable. It raises the possibility that immune activation, microbiome disruption, inflammatory signalling, or post-infectious neuroimmune mechanisms may have worsened an already vulnerable glutamate/NMDA system. This does not prove causality, but it fits a broader pattern: infection, inflammation, gut disruption, and metabolic stress can all shift neurotransmitter signalling and mitochondrial resilience. In a person whose glutamate receptors, NMDA signalling, antioxidant systems, or amino acid economy are already atypical, these triggers may push the system into a more rigid, compulsive, or excitotoxic state.

This is where the conventional psychiatric model reveals itself as too narrow. A person may be diagnosed with OCD or BDD, but the underlying mechanism could involve a convergence of:

• glutamate/NMDA signalling differences

• altered excitatory–inhibitory balance

• immune or post-infectious activation

• mitochondrial stress

• collagen and connective tissue demand

• glycine or serine insufficiency

• glutathione depletion

• dopamine-quinone stress

• gut disruption

• methylation imbalance

• calcium-channel sensitivity

Symptoms become a manifestation of impaired signal updating under metabolic and neurochemical pressure.

This also explains why glycine could theoretically help one subgroup while being inappropriate, ineffective, or poorly tolerated in another. This is because glycine supports NMDA receptor function, its effects depend on the state of the system it enters. If NMDA signalling is functionally underpowered, glycine may improve signalling and neural updating. However, if the glutamate system is already overactivated, poorly cleared, inflamed, or calcium-dysregulated, the outcome could be different.

This is also why high-dose glycine should not be casually interpreted as a universal intervention. The doses used in the case report - 50 to 65 grams per day - are pharmacological, not nutritional. Even OCD researchers discussing glycine have noted that the very high doses required for central effects can be difficult to tolerate, particularly because of gastrointestinal side effects such as nausea.

The real importance of this case is that it exposes a missing layer in how we think about divergent mental health. It suggests that in some people, psychiatric symptoms may reflect failures in biochemical signalling, metabolic buffering, receptor dynamics, collagen demand, antioxidant capacity, and neuroimmune stability.

A working hypothesis would be:

In metabolically and/or neurodevelopmentally divergent individuals, obsessive-compulsive and body-focused symptoms may arise when altered glutamatergic signalling, NMDA receptor dynamics, immune activation, and amino acid economy disruption converge. Glycine is relevant because it is both a structural substrate for collagen and a signalling substrate for NMDA receptor function, placing it at the crossroads of connective tissue integrity, oxidative stress buffering, and neural plasticity.

This does not erase psychology; it deepens it. Thoughts, compulsions, sensory distortions, and body-image distress are the classic psychologically relevant presentation. However they do not arise in a biochemical vacuum. The brain that loops, checks, fears, scans, or fixates is also a body managing inflammation, amino acid demand, mitochondrial stress, collagen turnover, neurotransmitter signalling, and environmental load.

For divergent people, this matters even more. If divergent biology includes altered glutamate receptor signalling, altered sensory thresholds, atypical excitatory–inhibitory balance, higher oxidative burden, connective tissue vulnerability, mitochondrial stress, or metabolic inflexibility, then psychiatric symptoms may often be downstream of a more complex terrain. This does not mean all divergent people need glycine. It means the amino acid, glutamate, collagen, and NMDA layers deserve far more attention than they currently receive.

The larger implication is this:

Divergent distress may not be a 'disorder' of thought. Sometimes it may be a divergence of signalling, substrate availability, and system buffering under the stress of an intolerable normative-standard load.

Glycine happens to sit almost exactly where those systems meet.

Link to study: https://pubmed.ncbi.nlm.nih.gov/20182547/

Artist: Charles Bell, Anatomy of the Brain

Contact

Reach out with questions or collaboration ideas.

Email

AChambers@divergentgenomics.org

© Alexandra Chambers 2026. All rights reserved.